Development of and Recovery from Secondary Hypogonadism in Aging Men: Prospective Results from the EMAS.

نویسندگان

  • Giulia Rastrelli
  • Emma L Carter
  • Tomas Ahern
  • Joseph D Finn
  • Leen Antonio
  • Terence W O'Neill
  • Gyorgy Bartfai
  • Felipe F Casanueva
  • Gianni Forti
  • Brian Keevil
  • Mario Maggi
  • Aleksander Giwercman
  • Thang S Han
  • Ilpo T Huhtaniemi
  • Krzysztof Kula
  • Michael E J Lean
  • Neil Pendleton
  • Margus Punab
  • Dirk Vanderschueren
  • Frederick C W Wu
چکیده

CONTEXT Secondary hypogonadism is common in aging men; its natural history and predisposing factors are unclear. OBJECTIVES The objectives were 1) to identify factors that predispose eugonadal men (T ≥ 10.5 nmol/L) to develop biochemical secondary hypogonadism (T < 10.5 nmol/L; LH ≤ 9.4 U/L) and secondary hypogonadal men to recover to eugonadism; and 2) to characterize clinical features associated with these transitions. DESIGN The study was designed as a prospective observational general population cohort survey. SETTING The setting was clinical research centers. PARTICIPANTS The participants were 3369 community-dwelling men aged 40-79 years in eight European centers. INTERVENTION Interventions included observational follow-up of 4.3 years. MAIN OUTCOME MEASURE Subjects were categorized according to change/no change in biochemical gonadal status during follow-up as follows: persistent eugonadal (n = 1909), incident secondary hypogonadal (n = 140), persistent secondary hypogonadal (n = 123), and recovered from secondary hypogonadism to eugonadism (n = 96). Baseline predictors and changes in clinical features associated with incident secondary hypogonadism and recovery from secondary hypogonadism were analyzed by regression models. RESULTS The incidence of secondary hypogonadism was 155.9/10 000/year, whereas 42.9% of men with secondary hypogonadism recovered to eugonadism. Incident secondary hypogonadism was predicted by obesity (body mass index ≥ 30 kg/m(2); odds ratio [OR] = 2.86 [95% confidence interval, 1.67; 4.90]; P < .0001), weight gain (OR = 1.79 [1.15; 2.80]; P = .011), and increased waist circumference (OR = 1.73 [1.07; 2.81], P = .026; and OR = 2.64 [1.66; 4.21], P < .0001, for waist circumference 94-102 and ≥102 cm, respectively). Incident secondary hypogonadal men experienced new/worsening sexual symptoms (low libido, erectile dysfunction, and infrequent spontaneous erections). Recovery from secondary hypogonadism was predicted by nonobesity (OR = 2.28 [1.21; 4.31]; P = .011), weight loss (OR = 2.24 [1.04; 4.85]; P = .042), normal waist circumference (OR = 1.93 [1.01; 3.70]; P = .048), younger age (< 60 y; OR = 2.32 [1.12; 4.82]; P = .024), and higher education (OR = 2.11 [1.05; 4.26]; P = .037), but symptoms did not show significant concurrent improvement. CONCLUSION Obesity-related metabolic and lifestyle factors predispose older men to the development of secondary hypogonadism, which is frequently reversible with weight loss.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Decreased serum testosterone level was not significantly correlated with lipid indices in elderly men

Background: Aging in men causes a gradual decline in endogenous testosterone levels, which may have detrimental effects on their health status. Testosterone deficiency is thought to promote atherosclerosis by modulating lipid metabolism. Therefore, this study was conducted to evaluate the serum testosterone level and its correlation with lipid profile in men aged ≥60 years old. Methods: All el...

متن کامل

Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS).

CONTEXT Late-onset hypogonadism (LOH) has been defined as a syndrome in middle-aged and elderly men reporting symptoms in the presence of low testosterone (T). OBJECTIVE The objective of the study was to seek objective biochemical and end-organ evidence of androgen deficiency in men classified as having LOH according to our previously published criteria. DESIGN, SETTING, AND PARTICIPANTS Th...

متن کامل

EMAS position statement: Testosterone replacement therapy in the aging male‏.

INTRODUCTION Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, characterized by the presence of symptoms (most usually of a sexual nature, such as decreased libido, decreased spontaneous erections and erectile dysfunction) and signs, in combination with low serum testosterone concentrations. Whether testosterone replacement therapy (TRT) should be offered to thos...

متن کامل

Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism.

BACKGROUND No randomized study exists comparing the effects of different modes of androgen substitution on bone mineral density (BMD). METHODS We performed a prospective, randomized, trial assigning 53 hypogonadal men to the following treatment groups: mesterolone 100 mg p.o. daily, testosterone undecanoate 160 mg p.o. daily, testosterone enanthate 250 mg i.m. every 21 days, or a single subcu...

متن کامل

LHRH THERAPY IN TEN MALE AND TEN FEMALE PATIENTS

We treated ten men and ten women suffering from hypogonadotropic hypogonadism with LHRH. Our method of treatment differed 'from others in that a mini pump was not available at the onset of the study. Nine women were given injections via a heparinized indwelling catheter every 120 minutes for 14 days, i,e. the proliferative phase. After ovulation, 3000 IU human chorionic gonadotropin (HCG) ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of urology

دوره 194 5  شماره 

صفحات  -

تاریخ انتشار 2015